samedan logo
 
 
spacer
home > ebr > spring 2008 > twenty-first century recruits
PUBLICATIONS
European BioPharmaceutical Review

Twenty-First Century Recruits

Talent acquisition today poses numerous challenges and opportunities for the life sciences industry. Pete Leddy of Invitrogen explores the changing world of pharmaceutical recruitment

Recruiting and retaining top employees is critical in order to secure a company’s continued success. As the biotechnology industry grows and expands, its talent needs rapidly increase, while the pool of qualified, diverse applicants is shrinking. This article explores the overall environment for talent acquisition (TA) in the life sciences and discusses why a solid TA plan is essential to achieving business goals. It will focus on a few of the challenges and experiences faced by the industry over the next few years, and will outline the resources that companies have at their disposal to attract and retain top talent.

BUSINESS GOALS IN THE SHORT AND LONG TERM

In developing a talent acquisition plan, companies must examine both long- and short-term business goals in order to align any hiring with those goals. What must a company accomplish in order to grow? The answer to that question will evidently vary significantly from company to company. Biotechnology and pharmaceutical companies poised to enter the clinic must be adept at planning clinical trials and working with regulatory agencies such as the US Food and Drug Administration (FDA) or the European Medicines Agency (EMEA). On the other hand, biotechnology tools companies seeking to offer ever more advanced technologies to life sciences researchers must continue to invest in newer technologies and build strong infrastructures to meet the demands of their customers.


Read full article >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Pete Leddy is Senior Vice President of Human Resources for Invitrogen, where he oversees global HR strategy and manages all aspects of the field. Prior to joining Invitrogen in 2005, Pete served as Vice President of Human Resources for the Americas operations of Dell Incorporated. He holds a PhD and a Master of Science degree in Industrial Organizational Psychology from the Illinois Institute of Technology.
spacer
Pete Leddy
spacer
spacer
Print this page
Send to a friend
Privacy statement

Industry Events

4th Annual Patient Recruitment and Retention in Clinical Trials

13-15 October 2008, Amsterdam

Patient recruitment is now consuming thirty percent of clinical trial time - more time than any other clinical trial activity - and almost half of all trial delays result from patient recruitment problems. As the recruiting culture becomes more sophisticated and the forces affecting patient enrollment grow more numerous and complex, pharmaceutical companies are striving to discover new strategies to facilitate enrollment in clinical trials. With increasing industry pressure to develop, test and market greater numbers of new drugs faster, pharmaceutical companies need to perform clinical trials as quickly as possible. Inefficient patient recruitment processes is a formidable barrier to pharmaceutical companies' success in launching new products. Improving the patient recruitment process is imperative to avoid wasted investments and eliminate costly delays in bringing new drugs to market -- today and even more so in the not-so-distant future. Improved patient recruitment presents one of the largest opportunities for pharmaceutical companies to eliminate delays in clinical trials, thereby making it possible to reduce time to market.  With patent time limits and large overheads meaning that any delays in the development timeline can be disastrous, a good understanding of how to successfully recruit patients for trials is vital for any company looking to succeed.
More info >>

 
News and Press Releases

Azopharma Product Development Group, Inc

HOLLYWOOD, Fla. – Azopharma Product Development Group, Inc. (“Azopharma”) announced today the addition of innovative state-of-the-art equipment at its formulation and manufacturing division, ApiCross Drug Delivery Technologies in Hollywood, Florida. The most recent acquisition is the MG Futura Capsule Filler which delivers the latest in capsule filling technology. The company has also added a Bausch & Strobel Aseptic Filling Isolator, equipment that is ground-breaking in the powder filling process. These additions support our previously implemented XcelodoseTM powder micro-dosing system. With these technologies, Azopharma is able to provide its clients with all forms of the capsule filling process. The new equipment is part of Azopharma’s recent manufacturing expansion which includes 17 new manufacturing suites for GMP, cytotoxic and aseptic products...
More info >>

 

©2000-2007 Samedan Ltd.
About Us | Register | Login | Site Map | Terms and Conditions | Contact Us |
Add to favourites

Print this page

Send to a friend
Privacy statement